Prairie Eye Center

Quick facts

Marketed products

• Cosopt PF 2%-0.5% Ophthalmic Solution · Ophthalmology
  Cosopt PF combines a topical carbonic anhydrase inhibitor (dorzolamide) and a beta-blocker (timolol) to reduce intraocular pressure through decreased aqueous humor production.
• Simbrinza 0.2%-1% Ophthalmic Suspension · Ophthalmology
  Simbrinza combines a beta-adrenergic antagonist and a carbonic anhydrase inhibitor to reduce intraocular pressure by decreasing aqueous humor production.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Prairie Eye Center portfolio CI brief
• Prairie Eye Center pipeline updates RSS